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We report a national  Pseudomonas aeruginosa  out-
break from a common source following piercings 
between July and September 2016 in England. The 
multi-agency outbreak investigation included active 
case finding, microbiological testing of environmen-
tal samples and case specimens including Variable 
Number Tandem Repeat (VNTR) typing and a retro-
spective cohort study. Overall, 162 outbreak cases (29 
confirmed, 14 probable and 119 possible) and 14 non-
outbreak cases were identified; all confirmed cases 
had ear piercings (93% cartilage). Outbreak cases 
were predominantly female (95%) and had a median 
age of 18 years (interquartile range: 13–56 years). 
Nineteen outbreak cases required surgery under 
general anaesthetic The same outbreak VNTR type 
(11,3,5,3,3,3,6,4,7) was isolated from bottles of an 
aftercare solution from a single manufacturer and in 
specimens from confirmed cases who attended eight 
different piercing studios supplied with this product. In 
the cohort study, use of aftercare solution was associ-
ated with becoming a case (aOR: 4.60, 95% confidence 
interval: 1.65–12.90). Environmental, microbiological 
and epidemiological investigations confirmed that 
contamination during production of aftercare solution 
was the source of this national outbreak; highlighting 
challenges in the regulation of a cosmetic products 
used in the piercing industry and that guidance on 
piercing aftercare may need to be reviewed.
Background
Pseudomonas aeruginosa  is a Gram-negative 
bacterium commonly found in water and a variety 
of wet environments [1]. Between August 2012 and 
December 2013, P. aeruginosa accounted for 3.5–11.0% 
of bacterial skin and skin-structure infections among 
hospitalised patients in 35 hospitals in the United 
Kingdom (UK) [2]. Sporadic  Pseudomonas  infections 
following body piercings are recognised but common 
source outbreaks are rarely reported [3,4]. Previous P. 
aeruginosa infections and outbreaks have been linked 
to exposure of the piercing wound to fresh water, 
swimming pools and use of a contaminated cleaning 
solution during the piercing procedure [3,5-7]. A cross-
sectional study in England estimated the prevalence of 
body piercing in adults at 10% [8]. Among those aged 
16 to 24 years, 31% of body piercings resulted in com-
plications, with 15% of piercings requiring professional 
help (i.e. from the piercer or healthcare professionals) 
and 0.9% of piercings resulting in hospital admission. 
Currently, no surveillance system for post-piercing 
infections exists in the UK.
Identification of the outbreak
On 31 August and 01 September 2016, the Public Health 
England (PHE) East Midlands and Surrey and Sussex 
Health Protection Teams (HPTs), South East England, 
were alerted by two local hospitals to a cluster of 
six and eight cases of ear abscesses, respectively, 
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following piercings at two piercing studios located 
150km apart. Four cases were confirmed with  P. aer-
uginosa  at each hospital site. Review of laboratory 
surveillance data indicated no other exceedances 
of P. aeruginosa  in East Midlands, South East England 
or nationally suggesting that the clusters could be 
associated with the two piercing studios rather than 
part of a wider outbreak.
A multi-agency national outbreak control meeting 
was convened on 8 September 2016 to investigate 
and prevent further infections. Due to the large dis-
tance between the two piercing studios, investigations 
focused on identifying if the causative strain was com-
mon to both piercing studios and if so, whether there 
was any common source exposure. An aftercare solu-
tion, referred to hereafter as aftercare solution X, pro-
duced by a single manufacturer in the East Midlands 
with nationwide distribution was rapidly identified as 
the probable source. Initial microbiological investiga-
tions identified a common Variable Number Tandem 
Repeat (VNTR) typing profile (11,3,5,3,3,3,6,4,7) 
of  P. aeruginosa  from isolates from confirmed cases 
attending either of the two piercing studios.
We describe the investigation and control measures 
taken for this national P. aeruginosa outbreak.
Methods
Case definitions
A sensitive case definition was used for case find-
ing, which did not specify attendance at piercing 
studios supplied with aftercare solution. Following 
strong microbiological evidence linking aftercare solu-
tion X with infection, case definitions were subse-
quently revised to accurately describe the extent of 
this outbreak, by distinguishing between outbreak and 
non-outbreak cases as shown in Box 1.
National case finding
A briefing note was issued to PHE staff including HPTs 
throughout England and sent to relevant authorities 
of the devolved administrations. A patient safety noti-
fication was also issued to all General Practitioners, 
Ear Nose & Throat Departments and Accident and 
Emergency departments in England. Clinicians 
were asked to consider the possibility of  P. aerugi-
nosa  in patients with piercing-site infections, provide 
appropriate treatment, and to report confirmed cases 
to their local HPT. Cases reported to HPTs were inter-
viewed using a standardised questionnaire to gather 
information on the piercing studio, type of piercing, 
the process used in the studio, aftercare advice and 
practice, products provided and if medical care for a 
post-piercing complication was sought.
Retrospective cohort study in two piercing 
studios, South East England and East Midlands
To test the hypothesis that aftercare solution X was 
associated with infection, we conducted a retrospec-
tive cohort study in the two piercing studios where 
the outbreak was first identified. Individuals aged 16 
years or older who had a body piercing between 1 July 
and 10 September 2016 at either South East England 
or East Midlands piercing studios were included. An 
online questionnaire was emailed to piercing studio 
clients on 3 October 2016 (South East England) and 
17 November 2016 (East Midlands). The questionnaire 
included questions on patient details, demographics, 
clinical history, use of medical services post-piercing, 
piercing details, use of aftercare solution X and poten-
tial water/aqueous exposures e.g. swimming pools.
Box 1  
Pseudomonas aeruginosa outbreak case definitions, July–September 2016, England 
Confirmed outbreak case: a person who had a laboratory confirmed P. aeruginosa infection with the outbreak Variable Number 
Tandem Repeat (VNTR) type (11,3,5,3,3,3,6,4,7) following a piercing (any part of the body), anywhere in England, between 1 July 2016 
and 30 September 2016.
Probable outbreak case: a person who had a laboratory-confirmed P. aeruginosa infection for which no VNTR typing was available, 
following a piercing (any part of the body), conducted at a studio known to have been supplied with aftercare solution X, between 1 
July 2016 and 30 September 2016.
Possible outbreak case: a person who had a piercing (any part of the body) conducted at a studio known to have been supplied with 
aftercare solution X between 1 July 2016 and 30 September 2016 with a self-reported infection at the site of the piercing that required 
antibiotics and/or surgical drainage and/or developed pus discharge, for which no laboratory confirmation was available.
Non-outbreak case: a person who had a laboratory confirmed P. aeruginosa infection with a type different from the outbreak VNTR 
type (11,3,5,3,3,3,6,4,7) following a piercing (any part of the body) conducted anywhere in England, OR where no VNTR typing was 
available, following a body piercing (any part of the body) conducted at a studio known not to have been supplied with aftercare 
solution X, between 1 July 2016 and 30 September 2016.
Exclusion criteria: a person who had a sample which tested negative for P. aeruginosa OR for whom no information about the piercing 
studio was available OR for whom no laboratory confirmation was available and who attended a studio not known to have been 
supplied with aftercare solution X.
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Different case definitions were used for the cohort study 
(Box 2). Cohort case definitions were piercing-based as 
individuals could report multiple piercings during the 
study period, in contrast to the person-based case 
definitions as described in  Box 1. Confirmed cases 
were identified by cross-matching data with the case 
finding line list and national laboratory surveillance 
data. Individuals who provided limited information or 
were confirmed with an infection other than P. aerugi-
nosa were excluded.
We performed univariable and multivariable analy-
sis using Pearson’s chi-squared test, Fisher’s exact 
test and logistic regression, as appropriate. Variables 
with a p value < 0.2 and a priori variables age, sex and 
cartilage piercing were considered for inclusion in the 
model using a backwards stepwise approach. We iden-
tified a final model using the likelihood ratio test and 
observing changes in odds ratios (ORs) to assess for 
plausible confounding and interactions between the 
most strongly associated variables.
Dose-response relationships of daily frequency and 
duration of aftercare solution X used were explored 
using a score test for linear trend, if appropriate [9]. 
A  post-hoc  sensitivity analysis was performed using 
a more specific case definition by excluding cases 
reporting a shorter duration of symptoms (i.e. pus dis-
charge < 8 days).
Environmental investigations
Environmental health officers (EHOs) visited the East 
Midlands and South East England piercing studios and 
with Trading Standards (a local government service 
that performs routine inspections based on consumer 
complaints, with the aim to support businesses and 
consumers) visited the manufacturing site of aftercare 
solution X. At the piercing studios, EHOs reviewed 
piercing procedures and sampled common products 
in use including environmental cleaning solutions, 
skin puncture needles, jewellery, piercing equipment 
and bottles (opened/unopened) of aftercare solution. 
At the manufacturing site of the aftercare solution X, 
EHOs reviewed the production process, sampled equip-
ment and materials used in the manufacturing process 
and examined documentation to determine the extent 
of the distribution chain. Environmental samples were 
sent to PHE Food, Water and Environmental (FWE) 
Microbiology Laboratories. Samples were handled 
based on methods of The Microbiology of Drinking 
Water (2010) – Part 8- Method for the Isolation and 
Enumeration of  Aeromonas  and  P. aeruginosa  by 
membrane filtration [10]. All environmental samples 
with presumptive  P. aeruginosa  were sent to the PHE 
Antimicrobial Resistance and Healthcare Associated 
Infections (AMRHAI) unit for confirmation and typing 
using VNTR analysis [11,12].
Microbiology investigations
Samples from affected cases were tested for  P. aer-
uginosa  by local NHS microbiology laboratories and 
isolates were sent to the AMRHAI reference unit for 
confirmation and typing by VNTR [11,12]. Antibiotic 
susceptibility testing was by agar dilution and results 
interpreted using European Committee on Antimicrobial 




In total, 188 individuals with infection following body 
piercing were identified during this outbreak (Figure 1); 
162 outbreak cases (29 confirmed, 14 probable and 119 
possible) and 14 non-outbreak cases. Twelve individu-
als were excluded. 
Outbreak cases were predominantly female (154/162, 
95%) and had a median age of 18 years (interquartile 
range (IQR) 13–56 years) (Figure 2). All 29 confirmed 
cases were ear piercings (93% cartilage, 7% ear site 
unknown).
Aftercare solution X was supplied to at least 38 piercing 
studios (36 in England, two in Scotland). Of these, 10 
gave rise to outbreak cases. Confirmed and probable 
cases were identified across England predominantly in 
South East England (n = 19) or East Midlands (n = 15) 
where the outbreak was first identified. No cases were 
identified in Scotland (Figure 3). 
Among outbreak cases where information was known, 
58/147 (39%) attended primary care, 52/153 (34%) 
attended hospital and 44/152 (29%) required a medi-
cal procedure; 19/147 (13%) required surgery under 
general anaesthetic, 20/147 (14%) required a medi-
cal procedure without general anaesthetic and 2/149 
(2%) required a medical procedure of unknown nature. 
Information on medical procedures was incomplete for 
17 cases.
Retrospective cohort study in two piercing 
studios, South East England and East Midlands
A total of 1,237 individuals were sent the online ques-
tionnaire, with 18% (n  =  222) responding, reporting 
a total of 235 piercings between them. Of these 222 
individuals, 114 individuals met the cohort case defi-
nition (Box 2) and were included in the cohort (attack 
rate: 49% among piercings). Of the 114 individuals, five 
cases were confirmed with  P. aeruginosa  infection of 
Box 2 
Pseudomonas aeruginosa outbreak cohort case definition, 
July–September 2016, England 
Cohort case definition: a piercing (any part of the body) 
conducted at the East Midlands or South East England 
piercing studios between 1 July 2016 and 10 September 
2016, in a person aged 16 years or older with a self-reported 
infection at the site of the piercing that required antibiotics 
and/or surgical drainage and/or developed pus discharge.
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which two were confirmed with the outbreak VNTR type 
and three had no VNTR typing data available. Thirteen 
respondents reported two piercings during the study 
period.
Most respondents (212/222) and cases (110/114) were 
female. Median age of respondents was 21 years (IQR: 
18–30 years). No difference in age (Wilcoxon rank-
sum test, p value  =  0.14) or sex (Fisher’s exact test, 
p value  =  0.53) between cases and non-cases was 
identified. Among cases, 51 (45%) were ear cartilage 
piercings, 16 (14%) were ear lobe piercings and 47 
(41%) were non-ear piercings. Cases most commonly 
reported pus discharge (n = 105; 92%) at the piercing 
site, with more than two weeks the most frequently 
reported duration (28%).
In the final multivariable model, use of aftercare 
solution X (aOR 4.60; 95% confidence interval (CI) 
1.65–12.87, p value  <  0.01), and any cream use (aOR 
5.89; 95% CI: 1.21–28.62, p value = 0.01) were strongly 
associated with becoming a case (Table 1); younger 
age was also found to be associated with becoming a 
case. No dose-response relationships were detected 
between the use of aftercare solution X and becom-
ing a case. The presence of an interaction between 
any cream use and aftercare solution X could not be 
explored due to small numbers.
Among the 114 cohort cases, 109 (96%) reported after-
care solution X use compared with 12 (11%) reporting 
any cream use, with no cases reporting cream use 
only. Nine cohort cases reported the use of different 
antibacterial/antiseptic creams and three reported the 
use of three different other creams. Median duration 
of aftercare solution X use did not significantly differ 
between cases and non-cases (20 days vs 15 days, 
p value  =  0.23). In the sensitivity analysis (excluding 
Figure 1
Individuals with infection following body piercing, England, July–September 2016 (n = 188)
188 individuals with infection after 
piercing identified through:
- 78 national case finding
- 114 cohort study
(4 in both sources)
163 individuals pierced at studios 










13 individuals pierced at studios 
not supplied with aftercare solution 
Exclusions:
- 6 unknown piercing studios
- 2 negative for P. aeruginosa
- 4 without P. aeruginosa 
confirmation and pierced in a 
studio not supplied with 
aftercare solution X
44 individuals with confirmed 
P. aeruginosa
- 29 confirmed outbreak cases
- 14 probable outbreak cases
- 1 non-outbreak case
a14 non-outbreak cases were identified who attended studios not known to be supplied with aftercare solution X (n = 13) and/or had a 
confirmed Pseudomonas aeruginosa infection with a different Variable Number Tandem Repeat (VNTR) strain from the outbreak cases (and 
were all distinct from each other) (n = 9).
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cases reporting a shorter duration of symptoms (i.e. 
pus discharge  < 8 days), similar results were obtained 
i.e. use of aftercare solution X (aOR: 6.03; 95% CI: 
1.35–27.04) and any cream use (aOR: 6.50; 95% CI: 
1.26–33.66).
Environmental investigations
Infection prevention and control procedures were sat-
isfactory at the East Midlands and South East England 
piercing studios. At the production site for the aftercare 
solution, environmental inspections identified inad-
equate quality control and documentation procedures. 
Aftercare solution X was a 100ml bottle of saline (0.9% 
sodium chloride) with the possible addition (upon 
request) of retail tea tree oil diluted with de-ionised 
water.
In total, 88 environmental samples were submitted for 
testing including bottles of aftercare solution X, jewel-
lery, puncture needles, liquids used during the piercing 
procedure, and samples from the manufacturing site. 
Twenty-one environmental samples were positive for P. 
aeruginosa  including unopened aftercare solution X 
bottles from studios (n = 10), opened aftercare solution 
X bottles from cases (n = 4) and environmental samples 
from the production equipment and materials at the 
manufacturing site of aftercare solution X (n = 7). High 
levels of P. aeruginosa (> 100 colony forming units (cfu) 
per ml) were isolated from all samples positive for  P. 
aeruginosa. To put this in context, levels  >  10 cfu per 
100ml are considered unsatisfactory in augmented 
care ward hot and cold water systems in the hospital 
setting and in swimming pool waters [14,15].
Microbiological investigations
The same outbreak VNTR type (11,3,5,3,3,3,6,4,7) 
was identified in the 21 environmental samples test-
ing positive for P. aeruginosa and in the 29 confirmed 
outbreak cases who visited a piercing studio supplied 
with aftercare solution X. This VNTR type had only 
previously been identified in three of 18,755 isolates 
tested by AMRHAI since 2010 and is therefore very 
Figure 2







































Aftercare product withdrawn from sale
A. Symptom onset week (n=138) B. Piercing week (n=166) 
a Cohort study ended on week 36; therefore, a decrease in number of cases as shown in (A) was expected.
b Week 24 started on 13 June 2016.
c Piercing week was missing for 10 cases.




Geographical distribution of 38 piercing studios in receipt of aftercare solution X with confirmeda, probableb and possiblec,d 




Possible (n=102, 17 missing)
East Midlands
South East
Contains Ordinance Survey data © Crown copyright and database right 2018. Contains Royal Mail data © Royal Mail copyright and database 
right 2018. Contains National Statistics data © Crown copyright and database right 2018.
19 confirmed and probable cases in the South East, and 15 confirmed and probable cases in the East Midlands.
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Table 1a
Univariable and multivariable associations between exposures and infection following body piercing among clients at two 
piercing studios, ranked by ascending aOR, East Midlands and South East England, July–September 2016 (n = 235 piercings, 
unless otherwise indicated)
Exposure Total Cases AR (%)
Univariable  
analysis Multivariable analysis p value
OR (95% CI) aORd (95% CI)
Cartilage piercing
No 119 63 53% Reference Reference NA
Yesa 116 51 44% 0.70 (0.42–1.17) 0.72 (0.40–1.29) 0.27
Age NA NA NA 0.97 (0.95-1.00) 0.97 (0.95-1.00) 0.02
Gender
Male 10 4 NA Reference Reference NA
Female 225 110 49% 1.43 (0.39-5.22) 1.89 (0.43-8.20) 0.39
Piercing tool (n = 223)
Piercing needle 201 92 46% Reference Reference NA
Piercing gun 22 16 NA 3.16 (1.19–8.40) 2.22 (0.78–6.33) 0.12
Aftercare solution X use
No 28 5 NA Reference Reference NA
Yes 207 109 53% 5.12 (1.87–13.98) 4.60 (1.65–12.87) 0.001
Cream usec
No 221 102 46% Reference Reference NA
Yes 14 12 NA 7.00 (1.53–32.01) 5.89 (1.21–28.62) 0.01
Other saline solution use
No 220 108 49% Reference NA NA
Yes 15 6 NA 0.69 (0.24–2.01) NA NA
Homemade saline use
No 163 77 47% Reference NA NA
Yes 72 37 51% 1.18 (0.68–2.06) NA NA
Soap use
No 220 107 49% Reference NA NA
Yes 15 7 NA 0.92 (0.32–2.64) NA NA
Antibacterial solution use
No 202 98 49% Reference NA NA
Yes 33 16 NA 1.00 (0.48–2.09) NA NA
Piercing site sprayed before/during procedure (n = 156)
No 92 45 49% Reference NA NA
Yes 64 33 52% 1.11 (0.59–2.10) NA NA
Time started using aftercare solution X (n = 233)
No aftercare solution X use 28 5 NA Reference NA NA
Same day as piercing 177 92 52% 4.98 (1.81–13.68) NA NA
One or more days after piercing 28 15 NA 5.31 (1.57–17.97) NA NA
Daily frequency of aftercare solution
No aftercare solution X use 28 5 NA Reference NA NA
Once a day 20 11 NA 5.62 (1.52–20.80) NA NA
Twice a day 118 54 46% 3.88 (1.38–10.90) NA NA
3 times a day 53 35 NA 8.94 (2.91–27.46) NA NA
4 times or more a day 16 9 NA 5.91 (1.48–23.56) NA NA
aOR: adjusted odds ratio; AR: attack rate; CI: confidence interval; NA: not applicable; OR:odds ratio.
a Cartilage piercing includes antihelix, anti-tragus, conch, daith, helix, rook or tragus piercings, or where individual indicated a cartilage 
piercing. Non-cartilage piercing includes earlobe piercings or non-ear piercings, e.g. nose, navel, tongue.
b At least five different products reported.
c Exposure to water corresponds to any exposure to hot tub, open water or swimming pool.
d Based on 223 observations and adjusted for age, sex, aftercare solution X use, cream use, piercing gun and cartilage piercing.
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unusual. Representatives tested were susceptible to 
amikacin, gentamicin, piperacillin-tazobactam, ceftolo-
zane/tazobactam, ceftazidime, imipenem, meropenem 
and colistin, with intermediate susceptibility to aztre-
onam, with intermediate susceptibility to aztreonam. 
The VNTR types for non-outbreak cases were all dis-
tinct from each other and from the outbreak strain.
Control measures
On 9 September 2016, the aftercare solution X manu-
facturer was issued with a notice to cease manufacture 
and supply of the product and subsequently volun-
tarily recalled the product from sale. EHOs removed 
aftercare solution X from all piercing studios known 
to be supplied. Piercing studios supplied with after-
care solution X were requested to contact clients to 
advise them to cease using the product. Among cohort 
respondents, 70% (150/215) reported awareness of the 
recall of aftercare solution X, predominantly via envi-
ronmental health (32%, 69/215) or the piercing studios 
(28%, 60/215). On 15 September 2016, a proactive pub-
lic press statement was issued to advise the public to 
cease using the product and seek medical attention 
if required, advice that was reiterated during media 
interviews.
Discussion
The investigation found strong environmental, microbi-
ological, and descriptive epidemiological evidence and 
supporting analytical epidemiological evidence that 
the large national outbreak of P. aeruginosa infections 
following piercings in England during 2016 was caused 
by the use of aftercare solution X.
VNTR typing was central to this outbreak investigation 
by identifying a common outbreak VNTR profile shared 
between cases, environmental samples (taken from 
the manufacturing site), and directly from bottles of 
aftercare solution X (opened and unopened). The out-
break VNTR type was distinct from cases found to be 
Exposure Total Cases AR (%)
Univariable  
analysis Multivariable analysis p value
OR (95% CI) aORd (95% CI)
Duration of aftercare solution X use (weeks; n = 230)
No aftercare solution X use 9 1 NA Reference NA NA
Up to 1 week 28 16 NA 10.67 (1.17–97.18) NA NA
Up to 2 weeks 50 26 NA 8.67 (1.01–74.52) NA NA
Up to 3 weeks 35 21 NA 12.00 (1.35–106.80) NA NA
Up to 4 weeks 27 11 NA 5.50 (0.60–50.44) NA NA
More than 4 weeks 81 35 43% 6.09 (0.73–50.96) NA NA
Type of piercing (n = 232)
Bar 101 54 53% Reference NA NA
Stud 90 43 48% 0.80 (0.45–1.41) NA NA
Other 41 16 NA 0.56 (0.27–1.17) NA NA
Exposure to water
No 191 92 48% Reference NA NA
Yes 44 22 NA 1.08 (0.56-2.07) NA NA
Exposure to hot tub
No 231 112 48% Reference NA NA
Yes 4 2 NA 1.06 (0.15–7.67) NA NA
Exposure to open water
No 215 105 49% Reference NA NA
Yes 20 9 NA 0.86 (0.34-2.15) NA NA
Exposure to swimming pool
No 197 94 48% Reference NA NA
Yes 38 20 NA 1.22 (0.61–2.44) NA NA
Application of aftercare solution X (n = 205)
Indirectly onto piercing site only 53 29 NA Reference NA NA
Directly onto piercing site only 116 61 53% 0.92 (0.48–1.76) NA NA
Indirectly and directly onto piercing site 36 18 NA 0.83 (0.35-1.93) NA NA
aOR: adjusted odds ratio; AR: attack rate; CI: confidence interval; NA: not applicable; OR:odds ratio.
d Based on 223 observations and adjusted for age, sex, aftercare solution X use, cream use, piercing gun and cartilage piercing.
Table 1b
Univariable and multivariable associations between exposures and infection following body piercing among clients at two 
piercing studios, ranked by ascending aOR, East Midlands and South East England, July–September 2016 (n = 235 piercings, 
unless otherwise indicated)
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unrelated to the outbreak i.e. pierced at studios not 
known to have been supplied with aftercare solution X.
The cohort study identified a four times higher odds 
of becoming unwell in individuals who used aftercare 
solution X compared with those who did not use after-
care solution X. Use of any cream was also identified 
as a risk factor for infection although it is unlikely that 
cream use was responsible for this outbreak. This is 
because: (i) only 11% of cases reported any cream use 
compared with 96% for aftercare solution X, (ii) the 
most commonly reported types of cream were anti-
bacterial/antiseptic creams indicating they were likely 
used in response to an infection although information 
on time of cream application was not collected, (iii) 
cases reported using different brands/types of cream 
rather than a single type.
There have been previous outbreaks of  P. aerugi-
nosa  infections linked to contaminated aftercare 
solutions [3,5-7]. During an outbreak in Oregon, United 
States (US), P. aeruginosa was cultured from a ‘single-
use’ disinfectant spray bottle being refilled repeatedly 
with contaminated water from a sink and used to clean 
the piercing gun and earrings [3]. In New York, US,  P. 
aeruginosa  was also cultured from an aftercare solu-
tion made on site and given to customers at a piercing 
studio [5]. In both these outbreaks cartilage piercings 
were associated with developing  P. aeruginosainfec-
tions. It is thought that upper ear cartilage piercings 
are susceptible to infection due to the lack of blood 
supply to the area and can be slow to heal [3,16]. In 
this outbreak, 27/29 (93%) of confirmed cases had an 
ear cartilage piercing, however, we found no associa-
tion between cartilage piercings and infections in the 
analytical study. This may be due to only five labora-
tory confirmed P. aeruginosa cases participating in the 
survey and therefore may have reduced our ability to 
detect cartilage piercings as a risk factor. We found 
an unprecedented number of complications; 44 cases 
requiring medical procedures compared with at least 
five reported in the Oregon outbreak and 15 reported 
in the New York outbreak.
There were several limitations in this outbreak inves-
tigation. Initial case definitions used for case finding 
were broad to ensure the outbreak investigation identi-
fied all likely cases. However, as a result we identified 
a number of non-outbreak cases and in the absence of 
routine surveillance data, we were unable to indicate 
whether this was an expected background rate. This 
potentially inflated the initial number of possible out-
break cases and so a refined case definition was devel-
oped to describe the outbreak. Even with the refined 
case definition, it is likely sporadic infections following 
piercings were incorrectly reported as possible cases 
in this outbreak.
The questionnaire was disseminated more than 3 
weeks following the recall of aftercare solution X from 
the market and several months following the original 
piercing dates which may have influenced their recall 
of information. In addition, the information sent to cli-
ents instructing them to stop using aftercare solution X 
was provided before the questionnaire was circulated; 
this likely influenced their responses. Despite these 
limitations, the findings from the cohort study were in 
line with the descriptive epidemiology, environmen-
tal and microbiological evidence, of the source being 
aftercare solution X and helped describe the high bur-
den of infections amongst consumers.
Aftercare products such as aftercare solution X, 
implicated in this outbreak, are regulated by Trading 
Standards as cosmetics rather than medicines. 
Aftercare solution X was described on the label as 
‘ideal for irrigation and wound cleansing after pierc-
ing’ and included a mark indicating a product that con-
formed to the legal standards of the European Economic 
Area (EEA). EU regulation (EC1223/2009) on cosmetic 
products states that it “should not endanger health 
and safety of consumers” and “should be produced 
according to good manufacturing practice” [17]. The 
regulation includes a requirement for manufacturers to 
produce a Cosmetic Product Safety Report, which must 
include information about the product’s microbiologi-
cal quality. EU guidance (SCCS/1416/11) for the testing 
of cosmetics ingredients and their safety evaluation 
states that “P. aeruginosa…must not be detectable” 
[18]. There was no quality control of the manufacturing 
process or assessment of the product’s microbiological 
quality.
Lessons learnt and future considerations
This outbreak investigation identified several non-out-
break cases of P. aeruginosa  infections after piercing, 
which may indicate a wider issue and is consistent 
with a previous study where 31% of pierced clients 
experienced complications such as infection, bleeding, 
allergy, tear or injury [8]. Further research would be 
useful to gain a better understanding of the rate of 
infections following piercing and the associated risk 
factors
Since aftercare solution X had a mark indicating its 
compliance to EEA standards, it would have been plau-
sible for the product to be distributed widely in Europe. 
There may be a case for greater regulation of the quality 
and safety of products used for wound cleansing in the 
piercing and tattoo industry in order to prevent poten-
tial European-wide outbreaks. As compliance to good 
manufacturing practice often seems less rigorously 
enforced for cosmetic products vs medicinal ones, 
this is an area where there needs to be a high degree 
of vigilance if outbreaks are suspected. Furthermore, 
this outbreak and the challenges in regulation, high-
light that guidance on piercing aftercare may need to 
be reviewed with renewed scrutiny of the evidence on 
the benefits of using saline solution in post-piercing 
aftercare.
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